HCP Educational Material:

practical considerations on how to use Requip-Modutab(ropinirole)

IE/RPL/0004/16(1) Date of preparation: October 2017

Overview

- Requip-Modutab indications
- Initiating Requip-Modutab and titrating to optimal therapeutic dose
- Switching patients to Requip-Modutab
- Maintenance and dose titration as Parkinson's disease progresses
- Special precautions and contraindications
- Tolerability
- Compliance

Requip-Modutab indications

Requip-Modutab is licensed for use in early or late-stage patients with Parkinson's disease

As monotherapy

Licensed for use in the treatment of early-stage Parkinson's disease

As initial therapy to delay the introduction of levodopa

As adjunct therapy

Licensed for use in later disease in combination with levodopa

When the effect of levodopa
- **Wears off**
- **Becomes inconsistent**

- Requip-Modutab is not recommended for use in children under 18 years of age due to a lack of data on safety and efficacy

Requip-Modutab SPC, www.medicines.ie , October 2017

Requip-Modutab is available in a range of tablet strengths

2 mg

4 mg

8 mg

Requip-Modutab SPC, www.medicines.ie , October 2017

Requip-Modutab: principles of therapy

Patients take only one dose of Requip-Modutab per day

Tablets of Requip-Modutab must NOT be chewed, crushed or divided

Patients are titrated through sub-therapeutic doses to a dose where symptom control is obtained

A therapeutic response may be observed from 4 mg.

Clinicians are advised to review the efficacy of treatment at 4 mg and then 8 mg before continuing to titrate a patient

The maximum licensed dose of Requip-Modutab is 24 mg per day

Requip-Modutab SPC, www.medicines.ie , October 2017

Initiating once-daily Requip-Modutab and titrating to optimal therapeutic dose

Titrating patients on once-daily Requip-Modutab

TITRATION

Step	Single daily dose
Week 1	**2 mg**
Week 2	**4 mg**

A therapeutic response may be seen at 4 mg once-daily.

If sufficient symptomatic control is not achieved or maintained at 4mg, titrate up by 2 mg weekly or longer to 8mg *

* At 8mg/day the patient's dose–response should be reviewed.

• Thereafter, if symptomatic control is not achieved/maintained, titration can proceed in increments of 2mg to 4mg at 2-weekly or longer intervals.

• Requip-Modutab has a wide therapeutic dose range.

•**Maximum** licensed daily dose of **24mg**.

Requip-Modutab SPC, www.medicines.ie , October 2017

Switching patients to Requip-Modutab

Switching to once-daily Requip-Modutab from ropinirole 3x-daily

Patients currently taking ropinirole 3x-daily can be switched *overnight* to once-daily Requip-Modutab

“Overnight switching” means finishing ropinirole 3x-daily one day and beginning an equivalent total daily dose of Requip-Modutab the following day

Requip-Modutab SPC, www.medicines.ie , October 2017

Switching patients from ropinirole 3x-daily to once-daily Requip-Modutab

Ropinirole 3x-daily total daily dose (mg)	Once-daily Requip-Modutab dose (total in mg)
0.75–2.25	2
3–4.5	4
6	6
7.5–9	8
12	12
15–18	16
21	20
24	24

Overnight switch

Requip-Modutab SPC, www.medicines.ie , October 2017

Switching from other dopamine agonists

If a clinician decides to switch a patient to Requip-Modutab from another dopamine agonist, they should follow the marketing authorisation holder's guidance[1]

Other dopamine agonists should be discontinued gradually by reducing the daily dose over the period of one week[1,2,3]

Once-daily Requip-Modutab can then be initiated and titrated up to an effective daily dose[1]

1. Requip-Modutab SPC, www.medicines.ie, October 2017
2. Pramipexole SPC, www.medicines.ie, October 2017
3. Rotigotine SPC, www.medicines.ie, October 2017

Maintenance and dose titration as Parkinson’s disease progresses

Levodopa dose-reduction

It may be possible to reduce gradually the dose of levodopa,depending on the clinical response

In clinical trials, the dose of levodopa was reduced by approximately 30% in patients receiving Requip-Modutab as adjunct [1,2]

1. Requip-Modutab SPC, www.medicines.ie, October 2017
2. Pahwa R *et al*. *Neurology* 2007;**68**:1108–15.

Special precautions and contraindications

Precautions related to all non-ergot-derived dopamine agonists

Precautions common to non-ergot-derived dopamine agonists

Sudden onset of sleep during daily activities ,in some cases without awareness or warning signs

Caution while driving or operating machinery

Hypotension: blood pressure monitoring is recommended

Compulsive behaviour

Patients with history/presence of major psychiatric disorders: Should not be treated unless potential benefit outweighs the risks

Avoid use of concomitant centrally active dopamine antagonists

Requip-Modutab SPC, www.medicines.ie , October 2017

Contraindications and special precautions specific to Requip-Modutab

Contraindications

Hypersensitivity to active substance or any of the excipients list in SmPC available on www.medicines .ie

Hepatic impairment

Severe renal impairment

Special precautions

Ropinirole clearance is decreased in the elderly, thus gradually increase the dose against the symptomatic response

Dopamine agonist withdrawal syndrome

Lactase deficiency, galactose intolerance, glucose-galactose malabsorption

Pregnancy and lactation

Hallucinations

CYP1A2 metabolism: dose adjustment when medicinal products known to inhibit CYP1A2 are introduced or withdrawn, or smoking is started or stopped.

Requip-Modutab SPC, www.medicines.ie , October 2017

Tolerability

Tolerability profile for monotherapy and adjunct therapy

	Use as monotherapy	Use as adjunct therapy
Psychiatric disorders		
Common (≥1/100,< 1/10)	Hallucinations	Hallucinations
Nervous system disorders		
Very common (≥1/10)	Somnolence	Dyskinesia
Common (≥1/100,< 1/10)	Dizziness (including vertigo), sudden onset of sleep	Somnolence, dizziness (including vertigo); sudden onset of sleep
Vascular disorders		
Common (≥1/100,< 1/10)		Hypotension, postural hypotension
Uncommon (≥ 1/1,000, < 1/100)	Hypotension, postural hypotension	
Gastrointestinal disorders		
Very common (≥1/10)	Nausea	
Common (≥1/100,< 1/10)	Constipation	Nausea, constipation
General disorders and administrative site conditions		
Common (≥1/100,< 1/10)	Peripheral oedema	Peripheral oedema

Requip-Modutab SPC, www.medicines.ie , October 2017

Compliance

Compliance with medication is important for the effective management of Parkinson's disease

- **Compliance** is the extent to which a patient's actual dosage administration corresponds to the prescribed regimen
- Missed and mis-timed doses are likely contribute to "on–off" fluctuations
- Consequences of non-compliance in Parkinson's disease include:
  - Erratic symptom control
  - motor fluctuations
  - impaired function and quality of life

Grosset et al. Mov Disord, 2009

Summary

- Initiating and titrating patients to an optimal therapeutic dose of once-daily Requip-Modutab is simple
- Patients can be switched overnight from ropinirole 3x-daily to an equivalent total daily dose of once-daily Requip-Modutab
- Once-daily Requip-Modutab has a wide dose range of 2 mg to 24 mg, which may help patients maintain effective symptom control as Parkinson's disease progresses over time
- Once-daily Requip-Modutab is a dopamine agonist and has a tolerability profile typical of a non-ergot-derived dopamine agonist
- Once-daily Requip-Modutab offers the patient a simple dosing regimen with the potential to aid compliance

Requip-Modutab SPC, www.medicines.ie , October 2017

For more details on undesirable effects, please see SmPC.

Marketing Authorisation (MA) Holder: GlaxoSmithKline (Ireland) Ltd, 12 Riverwalk, Citywest Business Campus, Dublin 24. MA Nrs: PA 1077/37/6, 8 & 9. Legal category: POM S1B. Last date of revision: August 2015. Code: IE/RPL/003/144(1). Further information available on request from GlaxoSmithKline, 12 Riverwalk, Citywest Business Campus, Dublin 24. Tel: 01-4955000.

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at www.hpra.ie. Adverse reactions can also be reported to the HPRA by calling (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.